Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line erlotinib versus the reverse sequence

O. Fiala, M. Pesek, J. Finek, L. Benesova, Z. Bortlicek, M. Minarik,

. 2013 ; 33 (8) : 3397-3402.

Jazyk angličtina Země Řecko

Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc14040649

BACKGROUND: Pemetrexed and erlotinib represent novel agents for the treatment of non-small cell lung cancer (NSCLC). The role of sequential treatment in NSCLC has not been elucidated yet. We compared the efficacy of second-line pemetrexed followed by third-line erlotinib (P-E) to treatment with the reverse sequence (E-P). PATIENTS AND METHODS: We analyzed data of 57 patients with advanced-stage (IIIB/IV) lung adenocarcinoma harboring wild-type epidermal growth factor receptor (EGFR) gene; 31 patients were treated with P-E and 26 patients with the E-P sequence. RESULTS: The median progression-free survival (PFS) for patients treated with P-E was 3.6 months vs. 7.8 months for patients treated with E-P (p=0.029). The median overall survival (OS) for patients treated with P-E was 7.9 months vs. 26.3 months for patients treated with E-P (p=0.006). CONCLUSION: The results proved a significant improvement of both PFS and OS for patients treated with the E-P sequence as compared to the P-E sequence.

000      
00000naa a2200000 a 4500
001      
bmc14040649
003      
CZ-PrNML
005      
20170411120701.0
007      
ta
008      
140107s2013 gr f 000 0|eng||
009      
AR
035    __
$a (PubMed)23898110
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Fiala, Ondřej $7 xx0209889
245    10
$a Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line erlotinib versus the reverse sequence / $c O. Fiala, M. Pesek, J. Finek, L. Benesova, Z. Bortlicek, M. Minarik,
520    9_
$a BACKGROUND: Pemetrexed and erlotinib represent novel agents for the treatment of non-small cell lung cancer (NSCLC). The role of sequential treatment in NSCLC has not been elucidated yet. We compared the efficacy of second-line pemetrexed followed by third-line erlotinib (P-E) to treatment with the reverse sequence (E-P). PATIENTS AND METHODS: We analyzed data of 57 patients with advanced-stage (IIIB/IV) lung adenocarcinoma harboring wild-type epidermal growth factor receptor (EGFR) gene; 31 patients were treated with P-E and 26 patients with the E-P sequence. RESULTS: The median progression-free survival (PFS) for patients treated with P-E was 3.6 months vs. 7.8 months for patients treated with E-P (p=0.029). The median overall survival (OS) for patients treated with P-E was 7.9 months vs. 26.3 months for patients treated with E-P (p=0.006). CONCLUSION: The results proved a significant improvement of both PFS and OS for patients treated with the E-P sequence as compared to the P-E sequence.
650    _2
$a adenokarcinom $x farmakoterapie $x genetika $x patologie $7 D000230
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a glutamáty $x terapeutické užití $7 D005971
650    _2
$a guanin $x analogy a deriváty $x terapeutické užití $7 D006147
650    _2
$a lidé $7 D006801
650    _2
$a nádory plic $x farmakoterapie $x genetika $x patologie $7 D008175
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a staging nádorů $7 D009367
650    _2
$a chinazoliny $x terapeutické užití $7 D011799
650    _2
$a erbB receptory $x genetika $7 D066246
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pesek, Milos $u -
700    1_
$a Finek, Jindrich $u -
700    1_
$a Benesova, Lucie $u -
700    1_
$a Bortlicek, Zbynek $u -
700    1_
$a Minarik, Marek $u -
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 33, č. 8 (2013), s. 3397-3402
856    41
$u https://pubmed.ncbi.nlm.nih.gov/23898110 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20140107 $b ABA008
991    __
$a 20170411121000 $b ABA008
999    __
$a ok $b bmc $g 1005045 $s 839161
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 33 $c 8 $d 3397-3402 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
LZP    __
$a Pubmed-20140107

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace